Acadian Asset Management LLC Has $3.88 Million Holdings in Ironwood Pharmaceuticals, Inc. $IRWD

Key Points

• Acadian Asset Management LLC increased its holdings in Ironwood Pharmaceuticals by 160.7%, now owning approximately 2.65 million shares valued at around $3.88 million.
• Irownwood Pharmaceuticals reported an earnings per share (EPS) of $0.14 for the last quarter, surpassing analysts' expectations of ($0.02) by $0.16, with a revenue of $85.24 million.
• Wall Street analysts have mixed ratings on Ironwood Pharmaceuticals, with a consensus rating of "Hold" and an average price target of $4.94.

Acadian Asset Management LLC raised its position in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 160.7% in the first quarter, according to its most recent filing with the SEC. The firm owned 2,645,189 shares of the biotechnology company's stock after purchasing an additional 1,630,726 shares during the quarter. Acadian Asset Management LLC owned approximately 1.63% of Ironwood Pharmaceuticals worth $3,878,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the stock. Point72 Asia Singapore Pte. Ltd. bought a new position in Ironwood Pharmaceuticals during the 4th quarter valued at $36,000. Simplicity Wealth LLC purchased a new position in Ironwood Pharmaceuticals during the 1st quarter worth $45,000. Dynamic Technology Lab Private Ltd purchased a new position in Ironwood Pharmaceuticals during the 1st quarter worth $57,000. Y Intercept Hong Kong Ltd raised its stake in shares of Ironwood Pharmaceuticals by 162.6% during the 1st quarter. Y Intercept Hong Kong Ltd now owns 39,782 shares of the biotechnology company's stock worth $58,000 after purchasing an additional 24,635 shares during the period. Finally, Wealth Enhancement Advisory Services LLC bought a new stake in shares of Ironwood Pharmaceuticals during the 4th quarter worth $59,000.

Ironwood Pharmaceuticals Stock Up 5.6%

Shares of Ironwood Pharmaceuticals stock opened at $1.31 on Monday. The company has a market cap of $212.78 million, a PE ratio of -26.19 and a beta of 0.32. The business has a 50 day moving average of $0.98 and a 200 day moving average of $0.96. Ironwood Pharmaceuticals, Inc. has a 52 week low of $0.53 and a 52 week high of $5.13.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last announced its earnings results on Thursday, August 7th. The biotechnology company reported $0.14 EPS for the quarter, beating analysts' consensus estimates of ($0.02) by $0.16. The company had revenue of $85.24 million during the quarter, compared to the consensus estimate of $62.02 million. Ironwood Pharmaceuticals had a negative return on equity of 2.46% and a negative net margin of 2.25%. Ironwood Pharmaceuticals has set its FY 2025 guidance at EPS. On average, research analysts anticipate that Ironwood Pharmaceuticals, Inc. will post 0.1 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. Wall Street Zen upgraded Ironwood Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Saturday, August 9th. Zacks Research lowered Ironwood Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Friday, September 5th. One analyst has rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $4.94.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.

Want to see what other hedge funds are holding IRWD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.